




# John C. Adkisson

## Principal, President and Chief Executive Officer

 Minneapolis, MN

 612-337-2533

 [adkisson@fr.com](mailto:adkisson@fr.com)

“John Adkisson is the trial supremo... Adkisson focuses on big-ticket pharmaceutical cases in district courts, although he also has ample post-grant lead counsel experience.”

— *Client testimonial, 2019 IAM Patent 1000*

“John Adkisson is very, very good. He’s unflappable in negotiations, he doesn’t bang his shoe on a podium, he comes across well and he’s persuasive to folks on the other side. He always takes a thoughtful approach, he’s not emotional, and he’ll say why if he disagrees.”

— *Client testimonial, 2017 Chambers and Partners*

## Overview

### About John

John C. Adkisson, the president and chief executive officer of Fish & Richardson P.C., is responsible for the firm’s strategic direction. He has a reputation for his in-the-trenches work ethic and passion for promoting Fish’s culture of innovation and teamwork. His priorities include expanding the firm’s global reach and continuing to offer extraordinary value to every client in every matter. Mr. Adkisson has been a member of the firm’s management committee since 2017 and served as the managing group leader for the firm’s 200-plus lawyer litigation group since 2017.

In addition to serving as president and CEO of the firm, Mr. Adkisson has 20-plus years of experience as a patent infringement litigator. Over the past decade, Mr. Adkisson has focused on high-stakes

pharmaceutical cases, including representing clients in Hatch-Waxman and the rapidly emerging field of biosimilar litigation. Mr. Adkisson has also acted as lead counsel in numerous post-grant proceedings before the Patent Trial and Appeal Board (PTAB).

Some of Mr. Adkisson's high-profile cases include helping Repligen Corp. and Massachusetts Institute of Technology win a \$65 million settlement from ImClone Systems. He was on the team that represented Coherus BioSciences Inc. and succeeded in getting three key patents covering AbbVie Inc.'s arthritis medication Humira® — the world's best-selling drug — invalidated by the PTAB in 2017.

As the managing group leader for the firm's litigation group, Mr. Adkisson played a pivotal role in investing in and shaping the firm's next generation of trial lawyers. He is a strong proponent of Fish's 1L Diversity Fellowship program, which awards scholarships and summer associate positions to diverse first-year law students.

Mr. Adkisson's contributions to the field of intellectual property law have been widely recognized. In 2020, *Law360* featured Mr. Adkisson in his new role as CEO. In 2015, *The National Law Journal* profiled his long-standing successful work on behalf of 3M Co. He has also been named a Minnesota Super Lawyer for the past six years and has been included in Best Lawyers in America® every year since 2015.

## Focus Areas

---

### Services

- Litigation
- Post-Grant
- ITC Litigation
- Patent Litigation
- Trade Secret Litigation

### Industries

- Life Sciences

## Education

---

J.D. *cum laude*, University of Wisconsin, Madison (1996) Member, *Wisconsin Law Review*

B.A. *cum laude*, University of Nebraska (1993)

## Experience

---

*Immunex Corp and Amgen Manufacturing, Ltd. et al v. Samsung Bioepis Co., Ltd.*, (D.N.J.) Serving as counsel for Samsung Bioepis against Immunex and Amgen in case involving ETICOVO, Samsung Bioepis's biosimilar product to Enbrel. Case is ongoing.

*Janssen Biotech, Inc. v. Samsung Bioepis, Co., Ltd.*, (D.N.J.) Served as counsel for Samsung Bioepis against Janssen in case involving Renflexis, Samsung Bioepis's biosimilar product to Remicade. Janssen dismissed all claims against Samsung Bioepis with prejudice in November 2017.

*Athena Diagnostics Inc. v. Mayo Clinic* (D. Mass.) Served as counsel for Mayo Clinic in patent case related to detection of autoimmune disorder in patients. Case dismissed in Mayo's favor on all counts in August 2017 and dismissal affirmed by Federal Circuit in 2019.

*Coherus BioSciences, Inc. v. AbbVie Biotechnology Ltd.*, IPR 2016-00172 (P.T.A.B.) Served as counsel for Petitioner Coherus Biosciences in IPR proceedings related to patents covering AbbVie dosing regimens related to Humira. All claims invalidated in Final Written Decisions issued in May and June 2017, cases settled in 2018.

*Gilead Sciences, Inc. v. AbbVie Inc.*, (D. Del.) Served as counsel for Gilead against AbbVie in case involving solid formulations of pharmaceutical products related to treatment of Hepatitis C. Case settled in 2016.

*Massachusetts Institute of Technology and Repligen Corp. v. ImClone Systems, Inc.*, (D. Mass.) Obtained \$65 million settlement on morning of trial in September, 2007 in patent case in District of Massachusetts involving cancer drug Erbitux. Case reported in articles, "Twin Cities Lawyers Take On Most Bizarre Case of Their Lives in MIT v. ImClone Systems," and "Twin Cities Lawyers Score in Boston."

*Amarin Pharmaceuticals Ireland Ltd. v. Omthera Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals L.P.* (D. Del.) Counsel for Amarin Pharmaceuticals in patent case involving cholesterol-lowering drugs.

*The Regents of the University of Michigan and Repligen Corp. v. Bristol Myers Squibb*, (E.D. Tex.) Counsel for the University of Michigan and Repligen Corporation in patent case related to patent for method for treating rheumatoid arthritis.

*Arctic Cat v. Polaris and Polaris v. Arctic Cat* (D. Minn.) Lead counsel for Arctic Cat on series of patent infringement cases and PTAB proceedings related to off-road vehicles. Argued and obtained successful PTAB rulings on behalf of Arctic Cat. Cases currently pending in the District of Minnesota.

*3M Innovative Properties Co. v Avery Dennison Corp.*, (D. Minn.) Served as co-lead counsel for 3M in patent and antitrust cases related to retroreflective sheeting used on highway road signs. Argued and obtained successful *Markman* and summary judgment rulings on behalf of 3M. Cases settled in 2013.

*Halo LLC v. Pulse Engineering, Inc.*, (D. Nev.) Counsel for Halo LLC in patent case related to surface mount transformers used in electronics products. Case resulted in a jury verdict of willful infringement on Halo's behalf in November 2012 in the District of Nevada, affirmed by the United States Supreme Court in 2016.

*3M Innovative Properties Co. v. Avery Dennison Corp.*, (D. Minn.) Trial counsel for 3M in case tried to jury in Minneapolis in December, 2005. Jury returned verdict for 3M on all counts, permanent injunction granted in March, 2006.

*NUTech Ventures v. Syngenta Seeds, Inc.*, (D. Neb.) Counsel for NUTech Ventures (associated with the University of Nebraska-Lincoln) in patent case related to genetically modified corn. Argued and obtained successful *Markman* ruling on behalf of NUTech. Case settled in 2014.

## Insights

### Presentations

- "Biosimilars 2021 Year in Review," *Fish Webinar* (January 11, 2022)
- "Biosimilars – 2020 Year in Review," *Fish & Richardson Webinar* (January 2021)
- "Biosimilars: A 2020 Mid-Year Review," *Fish & Richardson Webinar* (July 2020)
- "Biosimilars: 2019 Mid-Year Update," *Fish & Richardson Webinar* (July 2019)
- "Biosimilars: A Year in Review," *Fish & Richardson Webinar* (January 2019)
- "Biosimilars: A Year in Review," *Fish & Richardson Webinar* (January 2018)
- "After *TC Heartland*: Venue Considerations for Practitioners," *Midwest IP Institute* (2017)
- "Biosimilars Litigation: A Midyear Review" *Fish & Richardson Boston Seminar Series* (August 2017)
- "U.S. Patent Litigation Five Years After The America Invents Act" *AIPLA Spring Meeting* (2016)

- “Post Grant Challenges at the PTO: Process and Strategy,” *Midwest Intellectual Property Institute* (2014)

## Publications

- “An Update On 2020 U.S. Biosimilars Regulation & Litigation,” *Biosimilar Development* (September 2020)
- “If You Snooze, Do You Lose Your Right To Sue?” *National Law Journal* (October 1998)

## Media Mentions

- “These Firms Are Landing The Most Patent Litigation Work,” *Law360* (May 19, 2022)
- “The Big Interview: John Adkisson, firm president and CEO of Fish & Richardson,” *Chambers Associate* (July 5, 2021)
- “3 Things Keeping Managing Partners Up At Night In 2021,” *Law360* (January 4, 2021)
- “How 7 IP Firms Weathered The COVID-19 Pandemic,” *Law360* (December 2020)
- “What Does the Future Hold for Intellectual Property in 2021?,” *Law.com* (December 2020)
- “Six IP Firms Reveal Post-COVID Management Plans,” *Managing IP* (July 24, 2020)
- “Law Firm Leaders: Fish & Richardson’s John Adkisson,” *Law360* (June 17, 2020)

## Recognition

- Recognized as a notable practitioner in Intellectual Property, *Chambers USA: Minnesota* (2022)
- Named a Lawyer of the Year, Litigation – Patent, Minneapolis, *The Best Lawyers in America* (2021-2022)
- Selected as a *Best Lawyer In America* (2015-2022)
- Named a “Life Sciences Star” by *LMG Life Sciences* (2018-2021)
- Named a “Super Lawyer” by *Super Lawyers* (2012-2014, 2016-2021)
- Named a “Leading Patent Professional” by *IAM Patent 1000* (2020-2021)
- Named a “Healthcare/Life Sciences Trailblazer” by *The National Law Journal* (2020)
- Named a “Attorney of the Year” by *Minnesota Lawyer* – Individual & Group Award Recipient (2018)

## Memberships & Affiliations

---

Member of the American Bar Association

Federal Circuit Bar Association

American Intellectual Property Law Association (AIPLA)

Minnesota Intellectual Property Law Association